These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 3859213)

  • 1. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.
    Birnbaum J; Kahan FM; Kropp H; MacDonald JS
    Am J Med; 1985 Jun; 78(6A):3-21. PubMed ID: 3859213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thienamycin: development of imipenen-cilastatin.
    Kahan FM; Kropp H; Sundelof JG; Birnbaum J
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():1-35. PubMed ID: 6365872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of imipenem-cilastatin in neonates.
    Gruber WC; Rench MA; Garcia-Prats JA; Edwards MS; Baker CJ
    Antimicrob Agents Chemother; 1985 Apr; 27(4):511-4. PubMed ID: 3859243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem/cilastatin: the first carbapenem antibiotic.
    Lyon JA
    Drug Intell Clin Pharm; 1985 Dec; 19(12):895-9. PubMed ID: 3910385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
    Pastel DA
    Clin Pharm; 1986 Sep; 5(9):719-36. PubMed ID: 3530614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem/cilastatin: rationale for a fixed combination.
    Norrby SR
    Rev Infect Dis; 1985; 7 Suppl 3():S447-51. PubMed ID: 3863220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.
    Norrby SR; Alestig K; Björnegård B; Burman LA; Ferber F; Huber JL; Jones KH; Kahan FM; Kahan JS; Kropp H; Meisinger MA; Sundelof JG
    Antimicrob Agents Chemother; 1983 Feb; 23(2):300-7. PubMed ID: 6573157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of imipenem/cilastatin in normal volunteers.
    Drusano GL; Standiford HC
    Am J Med; 1985 Jun; 78(6A):47-53. PubMed ID: 3859215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of imipenem-cilastatin in neonates.
    Freij BJ; McCracken GH; Olsen KD; Threlkeld N
    Antimicrob Agents Chemother; 1985 Apr; 27(4):431-5. PubMed ID: 3859242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal penetration of N-formimidoyl thienamycin in normal rabbits: potentiation by coadministration of renal dipeptidase enzyme inhibitor.
    Chow AW; Finlay KR; Stiver HG; Carlson CL
    Antimicrob Agents Chemother; 1983 Apr; 23(4):634-6. PubMed ID: 6574725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activity of imipenem: the first thienamycin antibiotic.
    Kropp H; Gerckens L; Sundelof JG; Kahan FM
    Rev Infect Dis; 1985; 7 Suppl 3():S389-410. PubMed ID: 3931196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of staphylococcal pyelonephritis in rats with N-formimidoyl thienamycin.
    Guze PA; Kalmanson GM; Ishida K; Freedman LR; Guze LB
    Chemioterapia; 1984 Feb; 3(1):53-6. PubMed ID: 6598578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of imipenem/cilastatin sodium in gynecological infection].
    Iwaki M; Sato H; Makinoda S; Demise M; Tabata M; Yamaguchi T; Takaoka H; Shinkai N; Okubo H; Sato H
    Jpn J Antibiot; 1986 Jun; 39(6):1509-13. PubMed ID: 3463791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.
    Verpooten GA; Verbist L; Buntinx AP; Entwistle LA; Jones KH; De Broe ME
    Br J Clin Pharmacol; 1984 Aug; 18(2):183-93. PubMed ID: 6593092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology. Study group of imipenem/cilastatin sodium in the field of obstetric and gynecological infections].
    Matsuda S; Suzuki M; Hasegawa Y; Ninomiya K; Shimizu T; Maeda Y; Ichinoe K; Makinoda S; Sato H; Sato H
    Jpn J Antibiot; 1986 Jun; 39(6):1626-55. PubMed ID: 3531568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.
    Calandra GB; Hesney M; Brown KR
    Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Clissold SP; Todd PA; Campoli-Richards DM
    Drugs; 1987 Mar; 33(3):183-241. PubMed ID: 3552595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis.
    Reed MD; Stern RC; O'Brien CA; Yamashita TS; Myers CM; Blumer JL
    Antimicrob Agents Chemother; 1985 Apr; 27(4):583-8. PubMed ID: 3859245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal model for evaluating the convulsive liability of beta-lactam antibiotics.
    Williams PD; Bennett DB; Comereski CR
    Antimicrob Agents Chemother; 1988 May; 32(5):758-60. PubMed ID: 3395104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats.
    Sack K; Herhahn J; Marre R; Schulz E
    Infection; 1985; 13 Suppl 1():S156-60. PubMed ID: 3863794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.